Regeneron (REGN) Announces 1-Yr. Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium
Tweet Send to a Friend
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that positive detailed one-year results from the Phase 3 PANORAMA trial evaluating EYLEA® ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
